Krystal Biotech beats Q3 2026 estimates with revenue $127.3M (+30% YoY), diluted EPS $2.05, and maintains $400 million buyback
- Company disclosed a $1.2 billion cash balance in conjunction with its Q3 2026 earnings update.
- Issued 2026 operating expense guidance of $155–$165 million alongside its previously announced $400 million buyback.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.